A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Latest Information Update: 12 May 2025
At a glance
- Drugs KK 3910 (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Kyowa Kirin
Most Recent Events
- 04 May 2025 Status changed from not yet recruiting to recruiting.
- 19 Feb 2025 New trial record